Results for &quot;&quot;Gemtuzumab&quot;&quot;[mesh_terms]

The cure of leukemia through the optimist's prism.

Hagop M Kantarjian, Nitin Jain, Guillermo Garcia-Manero, Mary Alma Welch, Farhad Ravandi, William G Wierda, Elias J Jabbour

Cancer 2022;128(2):240-259

Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.

Francesco Lo Coco, Emanuele Ammatuna, Nélida Noguera

Clinical advances in hematology & oncology : H&O 2006;4(1):57-62, 76-7

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.

Francesco Lo-Coco, Massimo Breccia

Expert opinion on biological therapy 2011;11(2):225-34

Novel therapies for children with acute myeloid leukaemia.

A S Moore, P R Kearns, S Knapper, A D J Pearson, C M Zwaan

Leukemia 2013;27(7):1451-60

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.

Uwe M Martens, Axel Benner, Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Michael W M Kühn, Thomas Schroeder, Karin Mayer, Michael Lübbert, Mohammed Wattad, Katharina Götze, Lars Fransecky, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Mark Ringhoffer, Richard Greil, Bernd Hertenstein, Jürgen Krauter, David Nachbaur, Maisun Abu Samra, Sigrid Machherndl-Spandl, Nadezda Basara, Claudia Leis, Anika Schrade, Silke Kapp-Schwoerer, Sibylle Cocciardi, Lars Bullinger, Felicitas Thol, Michael Heuser, Peter Paschka, Verena I Gaidzik, Maral Saadati, Richard F Schlenk, Konstanze Döhner, Arnold Ganser

The Lancet. Haematology 2023;10(7):e495-e509

Myelodysplastic syndromes and acute myeloid leukemias in the elderly.

Beatrice U Mueller, Katja Seipel, Thomas Pabst

European journal of internal medicine 2019;58():28-32

Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.

Wei-Ying Jen, Naval G Daver, Maro Ohanian, Guillermo Montalban-Bravo, Koichi Takahashi, Yesid Alvarado, Jan Burger, Musa Yilmaz, Nicholas J Short, Hagop M Kantarjian, Hussein A Abbas, William Wierda, Sherry Pierce, Mark Brandt, Steven Kornblau, David McCue, Koji Sasaki, Keyur Patel, Farhad Ravandi, Gautam Borthakur, Elias Jabbour, Courtney D DiNardo, Naveen Pemmaraju, Nitin Jain, Alessandra Ferrajoli, Prithviraj Bose, Tapan M Kadia, Guillermo Garcia-Manero, Ghayas C Issa, Jennifer Marvin-Peek, Danielle Hammond, Abhishek Maiti, Kelly Chien, Fadi Haddad, Lucia Masarova, Mahesh Swaminathan

Cancer 2025;131(1):e35662

Acute promyelocytic leukemia: what are the treatment options?

Felicetto Ferrara

Expert opinion on pharmacotherapy 2010;11(4):587-96

Role of arsenic trioxide in acute promyelocytic leukemia.

John F Seymour, Harry J Iland

Current treatment options in oncology 2014;14(2):170-84

Treatment of relapsed or refractory acute promyelocytic leukemia.

Martin S Tallman

Best practice & research. Clinical haematology 2007;20(1):57-65

Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Akihiro Takeshita

International journal of hematology 2013;97(6):703-16

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

Dan Jones, Stefan Faderl, Guillermo Garcia-Manero, Srdan Verstovsek, Hagop Kantarjian, Elihu Estey, Alessandra Ferrajoli

Blood 2006;107(9):3469-73

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.

Walter Fiedler, Marie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, Jürgen Krauter, Daniela Weber, Margit Moessner, Claus-Henning Köhne, Heinz A Horst, Ingo G H Schmidt-Wolf, Mathias Rummel, Katharina Götze, Elisabeth Koller, Andreas L Petzer, Hans Salwender, Heinz Kirchen, Detlef Haase, Stephan Kremers, Matthias Theobald, Axel C Matzdorff, Arnold Ganser, Hartmut Döhner, Richard F Schlenk

Haematologica 2017;101(7):839-45

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.

Mikkael A Sekeres, Jaroslaw P Maciejewski, Harry P Erba, Manuel Afable, Ricki Englehaupt, Ronald Sobecks, Anjali Advani, Sherry Seel, Josephine Chan, Matt E Kalaycio

Cancer 2011;117(6):1253-61